Nuvation Bio Inc
Company Profile
Business description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Contact
1500 Broadway
Suite 1401
New YorkNY10036
USAT: +1 332 208-6102
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
273
Stocks News & Analysis
stocks
Insignia Financial: Revised deal still attractive
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,001.40 | 59.90 | 0.67% |
CAC 40 | 7,744.41 | 53.81 | -0.69% |
DAX 40 | 24,041.90 | 265.90 | -1.09% |
Dow JONES (US) | 44,502.44 | 179.37 | 0.40% |
FTSE 100 | 9,023.81 | 10.82 | 0.12% |
HKSE | 25,470.77 | 340.74 | 1.36% |
NASDAQ | 20,892.69 | 81.49 | -0.39% |
Nikkei 225 | 41,171.32 | 1,396.40 | 3.51% |
NZX 50 Index | 12,794.06 | 39.68 | -0.31% |
S&P 500 | 6,309.62 | 4.02 | 0.06% |
S&P/ASX 200 | 8,737.20 | 60.00 | 0.69% |
SSE Composite Index | 3,583.12 | 1.26 | 0.04% |